AstraZeneca (AZN) Bets Big on U.S. with $50 Billion Manufacturing Expansion

AstraZeneca PLC (NASDAQ:AZN) ranks among the stocks to benefit from an onshoring boom. AstraZeneca PLC (NASDAQ:AZN) announced on July 21 that it would invest $50 billion in the United States by 2030, becoming the most recent pharmaceutical company to make this commitment as impending tariffs threaten to drive up costs in the sector.

The company claims that plans for a new production facility specializing in chronic illnesses are part of the investment. The multibillion-dollar facility would support the company’s oral GLP-1s and the company’s metabolic and weight-management portfolio.

According to the company, the Virginia plant would be AstraZeneca’s biggest manufacturing investment in the world. The investments coincide with President Trump’s threats of levying tariffs of up to 200% on medications manufactured overseas. Before the tariffs take effect, companies would have up to a year and a half to reshore their supply lines.

AstraZeneca PLC (NASDAQ:AZN) is a prominent player in the pharmaceutical sector, especially for its work on rare disease and cancer treatments. The company has a strong reputation in the healthcare industry thanks to its history of medical advancements.

While we acknowledge the potential of AZN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

Read More: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds

Disclosure: None.